AU2015245743B2 - Process for the manufacturing of medicaments - Google Patents

Process for the manufacturing of medicaments Download PDF

Info

Publication number
AU2015245743B2
AU2015245743B2 AU2015245743A AU2015245743A AU2015245743B2 AU 2015245743 B2 AU2015245743 B2 AU 2015245743B2 AU 2015245743 A AU2015245743 A AU 2015245743A AU 2015245743 A AU2015245743 A AU 2015245743A AU 2015245743 B2 AU2015245743 B2 AU 2015245743B2
Authority
AU
Australia
Prior art keywords
chloro
afford
methyl
solvent
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015245743A
Other languages
English (en)
Other versions
AU2015245743A1 (en
Inventor
Alexandra CHESTAKOVA
Wei Gu
Hans Iding
Jing Li
Jinguang LIN
Xin Linghu
Patrik Meier
Chunbo SHA
Jeffrey Stults
Youchu Wang
Haiming Zhang
Jianqian ZHANG
Tao Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2015245743A1 publication Critical patent/AU2015245743A1/en
Priority to AU2020220208A priority Critical patent/AU2020220208B2/en
Application granted granted Critical
Publication of AU2015245743B2 publication Critical patent/AU2015245743B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
AU2015245743A 2014-04-09 2015-04-08 Process for the manufacturing of medicaments Ceased AU2015245743B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020220208A AU2020220208B2 (en) 2014-04-09 2020-08-21 Process for the manufacturing of medicaments

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014075011 2014-04-09
CNPCT/CN2014/075011 2014-04-09
PCT/CN2015/076083 WO2015154674A1 (en) 2014-04-09 2015-04-08 Process for the manufacturing of medicaments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020220208A Division AU2020220208B2 (en) 2014-04-09 2020-08-21 Process for the manufacturing of medicaments

Publications (2)

Publication Number Publication Date
AU2015245743A1 AU2015245743A1 (en) 2016-10-27
AU2015245743B2 true AU2015245743B2 (en) 2020-09-24

Family

ID=54287327

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015245743A Ceased AU2015245743B2 (en) 2014-04-09 2015-04-08 Process for the manufacturing of medicaments
AU2020220208A Ceased AU2020220208B2 (en) 2014-04-09 2020-08-21 Process for the manufacturing of medicaments

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020220208A Ceased AU2020220208B2 (en) 2014-04-09 2020-08-21 Process for the manufacturing of medicaments

Country Status (22)

Country Link
US (4) US20170022183A1 (OSRAM)
EP (2) EP3494971B1 (OSRAM)
JP (3) JP6723926B2 (OSRAM)
KR (3) KR20200038553A (OSRAM)
CN (3) CN106659721B (OSRAM)
AR (1) AR099989A1 (OSRAM)
AU (2) AU2015245743B2 (OSRAM)
BR (2) BR122020014933B8 (OSRAM)
CA (2) CA2945098C (OSRAM)
ES (1) ES2733495T3 (OSRAM)
HR (1) HRP20191306T1 (OSRAM)
IL (2) IL248205B (OSRAM)
MX (2) MX392460B (OSRAM)
MY (3) MY188526A (OSRAM)
NZ (1) NZ725450A (OSRAM)
PL (1) PL3129025T3 (OSRAM)
RU (1) RU2684102C2 (OSRAM)
SG (1) SG11201608421XA (OSRAM)
SI (1) SI3129025T1 (OSRAM)
TW (2) TWI678366B (OSRAM)
WO (1) WO2015154674A1 (OSRAM)
ZA (1) ZA201607066B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3321262T3 (da) * 2012-03-01 2021-01-25 Array Biopharma Inc Serin-/threoninkinasehæmmere
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015085007A1 (en) 2013-12-06 2015-06-11 Genentech, Inc. Serine/threonine kinase inhibitors
MY188526A (en) 2014-04-09 2021-12-18 Genentech Inc Process for the manufacturing of medicaments
HRP20200342T1 (hr) 2015-11-09 2020-06-12 Astrazeneca Ab Derivati dihidroimidazopirazinona korisni u liječenju raka
AU2017249229A1 (en) 2016-04-15 2018-10-04 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2019051296A1 (en) 2017-09-08 2019-03-14 Genentech, Inc. DIAGNOSTIC AND THERAPEUTIC METHODS OF CANCER
WO2019158579A1 (en) 2018-02-13 2019-08-22 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
EP3546447A1 (en) * 2018-03-29 2019-10-02 Heidelberg Pharma GmbH Synthesis of (2s,3r,4r)-4,5-dihydroxyisoleucine and derivatives
IL293382A (en) * 2019-12-05 2022-07-01 Astrazeneca Ab Process and intermediates for the production of formula (i)
CN115710158A (zh) * 2021-08-23 2023-02-24 凯特立斯（深圳）科技有限公司 一种不对称催化制备替格瑞洛中间体的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013130976A1 (en) * 2012-03-01 2013-09-06 Array Biopharma Inc. Serine/threonine kinase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
US6869966B2 (en) * 2002-09-30 2005-03-22 Banyu Pharmaceutical Co., Ltd. N-substituted-2-oxodihydropyridine derivatives
MX2008012413A (es) * 2006-03-29 2008-10-07 Hoffmann La Roche Derivados de piridina y pirimidina como antagonistas del receptor metabotropico de glutamato 2 (mglur2).
EP2205086B1 (en) * 2007-11-06 2013-08-14 E. I. du Pont de Nemours and Company Fungicidal heterocyclic amines
US9867667B2 (en) * 2014-02-27 2018-01-16 Canon Usa Inc. Placement apparatus
MY188526A (en) * 2014-04-09 2021-12-18 Genentech Inc Process for the manufacturing of medicaments

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013130976A1 (en) * 2012-03-01 2013-09-06 Array Biopharma Inc. Serine/threonine kinase inhibitors

Also Published As

Publication number Publication date
US20190367484A1 (en) 2019-12-05
CN111777594B (zh) 2023-06-27
KR20160133566A (ko) 2016-11-22
MY198371A (en) 2023-08-28
US20180134685A1 (en) 2018-05-17
CA2945098C (en) 2022-10-04
US11066389B2 (en) 2021-07-20
EP3129025A4 (en) 2018-01-17
EP3129025A1 (en) 2017-02-15
US20200190061A1 (en) 2020-06-18
EP3129025B1 (en) 2019-05-15
PL3129025T3 (pl) 2019-11-29
KR20230006043A (ko) 2023-01-10
MY188526A (en) 2021-12-18
ES2733495T3 (es) 2019-11-29
BR122020014933B1 (pt) 2022-11-29
CA3167641A1 (en) 2015-10-15
CN112645927A (zh) 2021-04-13
MX2020010384A (es) 2022-05-19
JP2020114817A (ja) 2020-07-30
CN106659721B (zh) 2021-01-01
NZ725450A (en) 2022-08-26
MX2016013162A (es) 2017-04-27
SG11201608421XA (en) 2016-11-29
BR122020014933B8 (pt) 2022-12-13
IL268690A (en) 2019-10-31
AU2020220208B2 (en) 2022-03-17
KR102490955B1 (ko) 2023-01-19
TWI762806B (zh) 2022-05-01
EP3494971C0 (en) 2024-07-24
CA2945098A1 (en) 2015-10-15
IL248205B (en) 2019-09-26
SI3129025T1 (sl) 2019-08-30
AU2015245743A1 (en) 2016-10-27
BR112016023391A8 (pt) 2018-04-17
US20170022183A1 (en) 2017-01-26
ZA201607066B (en) 2018-05-30
IL248205A0 (en) 2016-11-30
TW201620897A (zh) 2016-06-16
MY196320A (en) 2023-03-24
KR20200038553A (ko) 2020-04-13
WO2015154674A1 (en) 2015-10-15
RU2016139286A3 (OSRAM) 2018-10-26
US11098028B2 (en) 2021-08-24
JP6723926B2 (ja) 2020-07-15
CN111777594A (zh) 2020-10-16
MX392460B (es) 2025-03-24
US10611753B2 (en) 2020-04-07
CN106659721A (zh) 2017-05-10
BR112016023391A2 (OSRAM) 2017-08-15
EP3494971A1 (en) 2019-06-12
JP6974524B2 (ja) 2021-12-01
TWI678366B (zh) 2019-12-01
EP3494971B1 (en) 2024-07-24
BR112016023391B1 (pt) 2022-08-09
RU2684102C2 (ru) 2019-04-04
HRP20191306T1 (hr) 2019-10-18
RU2016139286A (ru) 2018-05-15
JP2017510620A (ja) 2017-04-13
AU2020220208A1 (en) 2020-09-10
AR099989A1 (es) 2016-08-31
JP2021167321A (ja) 2021-10-21
TW201945358A (zh) 2019-12-01
MX375638B (es) 2025-03-06

Similar Documents

Publication Publication Date Title
AU2015245743B2 (en) Process for the manufacturing of medicaments
HK40007970A (en) Salts of erk inhibitors
HK40007970B (en) Salts of erk inhibitors
HK40039714B (zh) 用於制备药物的方法
NZ761260A (en) Crystalline salts of erk inhibitors
HK1233931A1 (en) Process for the manufacturing of medicaments
HK1233931B (en) Process for the manufacturing of medicaments
HK40039714A (en) Process for the manufacturing of medicaments
WO2025245089A1 (en) Processes for preparing tetralin compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired